title: A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood.
abstract: BACKGROUND
  Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas.
  
  
  METHODS
  We conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma. Eligible patients received a fixed daily dose of 0.15 mg/kg of ATO once a week, with each subsequent cohort of patients receiving an additional dose per week up to a planned frequency of ATO administration 5 days per week as tolerated. Twenty-four children were enrolled and 21 children were evaluable.
  
  
  RESULTS
  ATO was well tolerated throughout the entire dose escalation, resulting in confirmation of safety when administered 5 days per week during irradiation.
  
  
  CONCLUSIONS
  The recommended dose of ATO during conventional irradiation is 0.15 mg/kg given on a daily basis with each fraction of radiation therapy administered.
authors: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bloomberg 11379, 1800 Orleans St, Baltimore, MD 21287, USA. kcohen@jhmi.edu
authors: Kenneth J
authors: KJ
authors: Cohen
authors: Iris C
authors: IC
authors: Gibbs
authors: Paul G
authors: PG
authors: Fisher
authors: Robert J
authors: RJ
authors: Hayashi
authors: Margaret E
authors: ME
authors: Macy
authors: Lia
authors: L
authors: Gore
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D001254:Astrocytoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D020295:Brain Stem Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy; D002648:Child; D002675:Child, Preschool; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D010087:Oxides / Q000627:therapeutic use*; D011379:Prognosis; D015996:Survival Rate; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide
keywords: arsenic trioxide; astrocytoma; chemoradiotherapy; pediatrics